India, Sept. 25 -- Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to report its third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open.
Investors are likely to focus on sales of key products, the impact of the Sanofi Development Balance repayment and pipeline progress.
Regeneron is a biotechnology company that develops and commercializes medicines for serious diseases, with programs spanning eye diseases, inflammatory diseases, cancer, cardiovascular, and metabolic diseases, neurological conditions and rare diseases.
Second Quarter 2026 Financial Results
In the second quarter of 2026, Regeneron reported net income of $1.30 billion, or $12.23 per share, compared with $1.39 bill...